Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool.
about
Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results)Heart disease and stroke statistics--2011 update: a report from the American Heart AssociationHeart disease and stroke statistics--2012 update: a report from the American Heart AssociationImproving cardiovascular risk reduction for primary prevention--utility of lifetime risk assessment.Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart AssociationEvaluation of the American Heart Association cardiovascular disease prevention guideline for women.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Predicted 10-year risk of cardiovascular disease is influenced by the risk equation adopted: a cross-sectional analysis.Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up studyStatin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006.Relationship between insulin resistance and coronary artery calcium in young men and women.Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006Novel cardiovascular risk prediction models in patients with systemic lupus erythematosus.Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis) potential implications for coronary risk assessment.2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study.Reproductive Risk Factors and Coronary Heart Disease in the Women's Health Initiative Observational Study.Cardiovascular disease prevention in women: are we up to date?Assessment of cardiovascular disease risk in South asian populationsThe incremental value of brachial flow-mediated dilation measurements in risk stratification for incident cardiovascular events: a systematic review.Role of coronary artery calcium score and coronary CT angiography in the diagnosis and risk stratification of individuals with suspected coronary artery disease.Comment on 'Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'.Adding a life-course perspective to cardiovascular-risk communication.The prevalence and distribution of coronary artery calcium in asymptomatic Korean population.Perception of cardiovascular risk and comparison with actual cardiovascular risk.Risk factors associated with metabolic syndrome and cardiovascular disease among women with polycystic ovary syndrome in Tabuk, Saudi Arabia.Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.
P2860
Q28744014-75FCD3E4-F0FE-4D0A-9820-DB9CCAA06363Q29547236-D18AFE28-3188-4C69-B3F3-085355790115Q29547909-A6DFBC76-111C-4479-9BC4-E3B9B9811031Q30451489-E724D989-3EFE-4075-9B6B-808191F95DB0Q30501645-5CE23E13-D145-4A3C-9AAE-31D2D026590DQ33737388-D40804E6-8576-4A06-B6D8-F9B85B21009BQ33972551-117F5672-F3BD-42BE-A864-E00A5E2CD58DQ34237508-01C4A046-0FBB-40C4-B3CF-B0D4E94113DEQ34273907-540E906A-3299-49BF-9236-4DF5A4D9C117Q34394584-1E7F58E4-3EF2-49FD-95AD-638AD4CF0D03Q34558449-559C9CB7-9CEE-4491-8897-8C27BF674F5CQ34683471-A3291E8E-4DF9-4289-9401-EA66B5E2589FQ35583185-D422778D-B074-4ACE-ACEE-9BC9C4C706DAQ35708425-A3076A07-218E-48AA-941A-0ABDFE2DF8E0Q36429024-3290CE7B-BEB2-42BE-83B7-D7DB370A89D3Q36781807-E20CE3D7-7AF3-40E2-86E5-7B616A05B1E4Q36957790-9D9C99AE-CA01-4F9B-9B18-845FC1B28B1EQ37040785-020EE89C-9154-43EE-8770-AA3B882AAC83Q37218645-769A2243-033D-4847-813E-42657BFC6324Q37876409-CC0EF6FB-868F-4F4D-9768-EDDF8626E0CFQ37885793-3272D2CC-884D-4F75-AA16-9A2C34E6A455Q42921920-4A4BA48A-86BE-45AE-A2FB-31FDE07FFC90Q44443163-2C3DCD9F-3BC9-4ED5-A2E9-D241ED331CC8Q44825898-05D7D206-8537-4626-BF40-1BB2AC2E9D0BQ46837010-2C6DD4CF-E5F5-4599-8EE0-B9C185BE71A0Q49166269-14E93527-4274-4A3D-A6F5-5F39F5F6C51CQ55053962-952835FE-6688-42C5-9B82-A78086108746
P2860
Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Who exceeds ATP-III risk thres ...... ATP-III risk assessment tool.
@en
Who exceeds ATP-III risk thres ...... ATP-III risk assessment tool.
@nl
type
label
Who exceeds ATP-III risk thres ...... ATP-III risk assessment tool.
@en
Who exceeds ATP-III risk thres ...... ATP-III risk assessment tool.
@nl
prefLabel
Who exceeds ATP-III risk thres ...... ATP-III risk assessment tool.
@en
Who exceeds ATP-III risk thres ...... ATP-III risk assessment tool.
@nl
P2860
P1433
P1476
Who exceeds ATP-III risk thres ...... ATP-III risk assessment tool.
@en
P2093
Jarett D Berry
Margaret W Cavanaugh-Hussey
P2860
P304
P356
10.1016/J.YPMED.2008.07.012
P407
P577
2008-07-29T00:00:00Z